Severe hypoglycaemia

/Severe hypoglycaemia

Connecting hypoglycemia and CVD risk

By: Dr. Lawrence Leiter |Date: 31 January 2019| Categories: Cardiovascular Disease, CV Risk, Severe Hypoglycaemia
Patients with diabetes remain at greatly increased risk of cardiovascular disease (CVD). Hypoglycemia from glucose-lowering medications, especially if severe, compounds the risk. While totally eliminating all diabetes-related hypoglycemia may be an overly ambitious goal, we could be doing more to reduce its occurrence.

Read More

Dead in bed syndrome

By: Simon Heller | Date: 30 October 2018| Categories: Dead in bed syndrome, Nocturnal Hypoglycaemia, Severe Hypoglycaemia, Type 1 Diabetes
Dead in bed syndrome understandably strikes terror in the hearts of people with type 1 diabetes and their families. Clinicians, for their part, may find it difficult to discuss the syndrome with patients and thus avoid the topic. Fortunately, the syndrome is rare enough that the key message to patients is reassurance.

Read More

Restoring Awareness, Reducing Severity: A strategic approach to mitigating the damage of hypoglycaemia

By: Stephanie Amiel, BSc, MD, FRCP |Date: Monday 30 April 2018| Categories: Severe Hypoglycaemia, Glucose-Monitoring Technology, Patient Education, Impaired Awareness
An awareness of hunger prompts people to open the refrigerator. The same process alows people to limit the damage of hypoglycaemia: a mental awareness of symptoms gives people a chance to take corrective action.

Read More

Giving Severe Hypoglycaemia the Attention it is Due

By: Yingying Luo, MD|Date: Tuesday 24 October 2017| Categories: ADVANCE trial, Cardiovascular events, DEVOTE study, glucose levels, Hypoglycemia Assessment Tool (HAT) study, ORIGIN trial, Patient education, Severe hypoglycaemia, Type 2 diabetes|
There is a line in the sand between mild and severe hypoglycaemia (SH). While mild hypoglycaemia is not trivial, it does not threaten life and health as SH does. For people who depend on insulin and other glucose-lowering drugs associated with hypoglycaemia, clinicians often consider a degree of SH “the cost of doing business” in diabetes management—in other words, an unwanted but unavoidable corollary of treatment.

Read More